BLUE is down -7%. Find out why the stock fell today.

Shares of Bluebird Bio (BLUE) are trading -7% lower at a price of $5.88 at the time of this writing. The stock is falling behind peers on a slightly glum day for the Health Care sector.

Recent catalysts the stock may be pull back from:
- Bluebird bio gets accelerated approval for SKYSONA gene therapy for cerebral adrenoleukodystrophy

Bluebird Bio has been trading between a 52-week high of $17.85 and a 52-week low of $2.87. The stock has a market cap of $453 Million.

bluebird bio is pioneering gene therapy with purpose. From its Cambridge, Mass., headquarters, they're developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond their labs, the company is working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.